Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Nanomedicine. 2017 Apr 17;13(6):1925–1932. doi: 10.1016/j.nano.2017.04.004

Figure 1. Cell and stroma binding properties of CGKRK.

Figure 1

A) Peptides CGKRK (top) and KAREC (bottom) labeled with FITC via aminohexanoic acid linker were used in the study; B) Confocal microscope images of cellular uptake of peptides following incubation with MB49 bladder carcinoma cells. MB49 cells show high accumulation of CGKRK inside the cytoplasm; C) KAREC does not show appreciable accumulation in the cells; D) quantification of the peptide uptake by fluorescence spectroscopy. CGKRK showed significantly more accumulation in the cells than KAREC (p-value 0.0001, non-paired 2-tailed t-test, n = 3 replicates, repeated 3 times); F-F) Binding of CGKRK and KAREC to heparin and collagen type I, respectively. Solid line, KAREC; dotted line, CGKRK. Collagen binding of CGKRK shows saturation kinetics; the other data sets show linear binding. The experiment was done in duplicate and repeated 2 times. CGKRK shows more efficient binding to both heparin and collagen type I, which are the main components of bladder matrix and bladder mucosa.